Hematology/Oncology

Top Story

FDA approves Revlimid for myeloma maintenance after stem cell transplant

February 22, 2017

The FDA today expanded the approval of lenalidomide to include maintenance therapy for patients with multiple myeloma who underwent autologous hematopoietic stem cell transplant.

Lenalidomide (Revlimid, Celgene) is the only FDA–approved treatment for maintenance after autologous HSCT.

In the Journals

Possible options for the future of health care

February 22, 2017
A perspective recently published in the New England Journal of Medicine provides some insight on what President Donald J. Trump can and cannot do, in light of his…
In the Journals

APRI, FIB4 guide esophageal varices screening in light of hemophilia, coinfection

February 22, 2017
The aspartate transaminase-platelet ratio index and Fibrosis-4 score were effective non-invasive markers to monitor fibrosis and correlated to the presence of esophageal…

Novel probe has potential to aid in margin detection during cancer surgery

February 22, 2017
Researchers in Australia have developed a novel optical fiber probe with high sensitivity for detecting and differentiating cancerous tissue from healthy tissue in…

Many patients lack knowledge about advances in cancer diagnostics, treatment

February 22, 2017
A majority of patients with cancer and their caregivers lack sufficient knowledge about advances in diagnostic and treatment options, according to results of a survey…
More News Headlines »
CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Video
Meeting News Coverage

VIDEO: Additional research necessary to define role of PARP inhibitors for BRCA–mutated breast cancer

January 9, 2017
More »
Featured
CME

Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents

This activity is supported by an educational grant from Novartis.

The identification and utilization of melanoma specific biomarkers continues to be of importance for diagnosis and…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement